ReviewInternational journal of molecular sciences2025
CD93 in Health and Disease: Bridging Physiological Functions and Clinical Applications.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- dia-PASEF Enables Rapid Profiling of the Human Secretome for Deeper Insights Into Cellular Dynamics and Inflammatory Mechanisms.Molecular & cellular proteomics : MCP · 2026Article
- Serum CD93 as a Potential Diagnostic Biomarker for Endometrial Cancer: A Case-Control Study.Journal of clinical medicine · 2026Article
- A transcriptomic and proteomic map of primary human cell types.Nucleic acids research · 2026Article
- Multi-omics analysis identifies oxidative stress-related biomarkers and therapeutic targets linking periodontitis and ulcerative colitis via the oral-gut axis.Frontiers in immunology · 2026Article
- Emerging hallmarks and the rise of complexities and heterogeneity of tumor.Biochemistry and biophysics reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
CD93 is a highly glycosylated transmembrane glycoprotein with key functional domains, including a C-type lectin-like domain (CTLD) and epidermal growth factor (EGF)-like domains. Primarily expressed in endothelial cells (ECs), CD93 regulates critical physiological processes such as angiogenesis, cell adhesion, migration, and apoptotic cell clearance through interactions with ligands like multimerin-2 (MMRN2) and insulin-like growth factor-binding protein 7 (IGFBP7). Aberrant CD93 expression has been observed in various pathological conditions, including inflammation, cardiovascular diseases, autoimmune disorders, and cancer. Notably, CD93 is overexpressed in tumor-associated blood vessels, which is associated with poor prognosis and advanced disease stages. Targeting the CD93 signaling pathway has the potential to improve tumor vascular function and enhance the efficacy of immunotherapy, making it a promising therapeutic target. This review summarizes the current understanding of CD93's structure, function, and disease mechanisms, providing a framework for further research and clinical translation in related fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.